ArticleCell death discovery2026
WWP1 gain-of-function drives developmental anoikis through TGFβ pathway during neurodevelopment.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The E3 ubiquitin ligase WWP1 orchestrates multiple cellular functions, yet the neurodevelopmental role and pathological implications of its dysregulation remain poorly defined, in contrast to its established oncogenic effects. Here, we demonstrate that hyperactive WWP1 induces neurodevelopmental abnormalities characterized by impaired neuronal migration and caspase-dependent cell death in the developing mouse brain and human neural progenitor cell models. Mechanistically, WWP1 gain-of-function (GOF) mutation disrupts cell adhesion, leading to anoikis, detachment-induced cell death. Pathway-level screening identifies TGFβ1 ligand treatment to restore cell survival in both neural progenitor cultures and embryonic mouse brains. Conversely, TGFβ pathway inhibition phenocopies WWP1-induced apoptosis, establishing that WWP1 hyperactivity promotes cell death via TGFβ pathway downregulation. Transcriptomic profiling of the WWP1 GOF cellular models confirms the downregulation of cell adhesion and TGFβ signaling pathway signatures, highlighting the necessity of balanced WWP1 activity during neurodevelopment. In addition, we identified a de novo WWP1 variant in a patient with developmental and epileptic encephalopathy. Biochemical and in vivo functional analyses characterize the variant as GOF, supporting the clinical relevance of WWP1 dysregulation in neurodevelopmental disorders. Together, these findings reveal WWP1 as a critical regulator of neuronal survival and adhesion, with its dysregulation disrupting key developmental processes in the human brain.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.